Skip to main content
. 2021 Sep 19;13(18):4701. doi: 10.3390/cancers13184701

Figure 2.

Figure 2

Selected bispecific T cell engaging constructs targeting BCMA and CD3. BCMA-targeting regions are colored red, CD3-targeting regions are blue. Fc regions are colored grey. (a) Bispecific T cell engager (BiTE®, AMG420). (b) Half-life extended bispecific T cell engager (HLE BiTE®, AMG701). (c) Bispecific antibody, IgG4 Fc region (REGN5458, Elranatamab). (d) Bispecific antibody, IgG4 Fc region (DuoBody®, Teclistamab). (e) Bispecific antibody, IgG4 Fc region, dual BCMA binding domains (TNB-383B). (f) Bispecific antibody, IgG1 Fc region, bivalent anti-BCMA arm (CC-93269).